Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Huamao Pharmaceutical

Request full access

Pharmaceutical ingredients and bioactives via synthetic biology.

Minhang District, ChinaFounded 1996Biotech & Life Sciences

About Huamao Pharmaceutical

Shanghai Huamao Pharmaceutical Co., Ltd., established in 1999, is a biopharmaceutical company located in Shanghai's Xinzhuang Industrial Park. The company is operated under the leadership of individuals including legal representative Wei Xiangchun and chairman Wei Zhe. What began as a specialized producer of pharmaceutical ingredients has evolved into a high-tech enterprise leveraging synthetic biology for a wide range of applications.

The company's history is marked by consistent growth and recognition. It was reportedly the first enterprise in China to produce medicinal lactose. Key milestones include receiving support from the Ministry of Science and Technology's innovation fund in 2003, achieving GMP certification in 2004 and renewing it in 2015, and being named a Shanghai high-tech enterprise in 2018. In June 2026, Consun Pharmaceutical announced a significant investment to acquire a 30% stake in Huamao, positioning it as a strategic associate and reinforcing its role as a key supplier.

Huamao's foundational business is the production of active pharmaceutical ingredients (APIs) and excipients. Its main products include a series of Dextran grades and USP-grade Lactose Monohydrate. Dextran 40 serves as a plasma expander in medical therapies, while other Dextran products have applications in bioscience and cryopreservation. The company's Lactose Monohydrate is a widely used excipient in pharmaceutical formulations, valued for its stability and cost-effectiveness. The firm utilizes an advanced membrane separation production process for its Dextran, which it has patented.

Building on its expertise in biopolysaccharides, the company has diversified into synthetic biology to produce high-value bioactive ingredients for the health and beauty sectors. This expanded portfolio includes substances like hydroxytyrosol, ectoine, ergothioneine, and salidroside. This strategic shift extends its business model from a B2B ingredient supplier to include OEM/ODM services, with an ambition to build an integrated industry chain from raw materials to consumer products.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Drug Development, Synthetic Biology, precision fermentation
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jun 2026 $26M $105M Consun ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Huamao Pharmaceutical in the Minhang District ecosystem

Live from Dealroom

The Huamao Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Consun
Employees 4 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Minhang District HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Huamao Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Huamao Pharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.